BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 49 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q2 2022. The put-call ratio across all filers is 0.17 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $6,714 | -36.5% | 19,834 | +5.9% | 0.00% | – |
| Q1 2024 | $10,578 | +73.0% | 18,732 | -38.7% | 0.00% | – |
| Q3 2023 | $6,116 | -73.5% | 30,563 | +117.5% | 0.00% | – |
| Q4 2022 | $23,049 | -30.2% | 14,054 | +16.3% | 0.00% | – |
| Q2 2022 | $33,000 | -57.1% | 12,085 | -37.4% | 0.00% | – |
| Q4 2021 | $77,000 | -25.2% | 19,300 | -38.1% | 0.00% | – |
| Q3 2021 | $103,000 | -48.8% | 31,200 | -41.1% | 0.00% | – |
| Q2 2021 | $201,000 | -47.2% | 52,943 | -46.9% | 0.00% | – |
| Q1 2021 | $381,000 | -65.6% | 99,700 | -59.3% | 0.00% | – |
| Q4 2020 | $1,108,000 | -68.7% | 244,833 | +17.0% | 0.00% | -100.0% |
| Q3 2020 | $3,541,000 | +96.8% | 209,300 | +30.4% | 0.00% | +100.0% |
| Q2 2020 | $1,799,000 | +665.5% | 160,453 | +216.6% | 0.00% | – |
| Q1 2020 | $235,000 | – | 50,685 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Perceptive Advisors | 400,000 | $1,068,000 | 0.09% |
| SABBY MANAGEMENT, LLC | 493,191 | $1,317,000 | 0.07% |
| GUARDIAN CAPITAL ADVISORS LP | 10,000 | $23,000 | 0.00% |
| A.R.T. Advisors, LLC | 22,758 | $60,000 | 0.00% |
| Psagot Value Holdings Ltd. | 22,715 | $61,000 | 0.00% |
| TCI Wealth Advisors, Inc. | 1,100 | $3,000 | 0.00% |
| Penserra Capital Management LLC | 4,980 | $13,000 | 0.00% |
| D'Orazio & Associates, Inc. | 500 | $1,000 | 0.00% |
| CITIGROUP INC | 380 | $1,000 | 0.00% |
| GEODE CAPITAL MANAGEMENT, LLC | 61,269 | $163,000 | 0.00% |